InsidersTradesSigma
Follow the Boston Scientific CORP stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Boston Scientific CORP has logged 555 reports. Market capitalisation: €72.3bn. The latest transaction was filed on 26 August 2026 (Acquisition). Among the most active insiders: Fitzgerald Joseph Michael. All data is openly available.
555
Insider Decl.
n/a
Thresholds
€10m
13 ops.
Buy Volume
€90m
106 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Boston Scientific CORP Buy (bullish), based on 29 analysts. Average price target: US$62.69.
52Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 7,983 of 28,958 companies
62.7
score / 100
Value54
Quality72
FCF yld5.0%
Earn yld4.3%
EV/EBITDA15.5x
ROE15%
Gross mgn69%
Net mgn14%
Debt/EBITDA2.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 26 August 2026
Declarations555 total
2,040 shares@ US$49.2195Common StockSEC:0001225208-26-007337:0
Canonical exit: 23 Nov 2026 (T+90)
2,930 shares@ US$51.190.0002% mcap17.3% of flowCommon StockSEC:0001225208-26-007084:0
9,908 shares@ US$50.460.0007% mcap46.9% of flowCommon StockSEC:0001225208-26-007062:0
2,100 shares@ US$47.5890.0001% mcap24.6% of flowCommon StockSEC:0001225208-26-007031:0
Canonical exit: 3 Nov 2026 (T+90)
140 shares@ US$48.58790.0000% mcap2.2% of flowCommon StockSEC:0001225208-26-006951:1
Canonical exit: 2 Nov 2026 (T+90)
186,240 shares@ US$48.33230.013% mcap12.9% of flowCommon StockSEC:0001225208-26-006950:0
Canonical exit: 1 Nov 2026 (T+90)
22,119 shares@ US$48.430.0015% mcap1.5% of flowCommon StockSEC:0001225208-26-006950:1
1,042 shares@ US$48.06550.0001% mcap16.4% of flowCommon StockSEC:0001225208-26-006951:0
Canonical exit: 1 Nov 2026 (T+90)
5,000 shares@ US$45.47990.0003% mcap11.0% of flowCommon StockSEC:0001225208-26-006882:0
Canonical exit: 29 Oct 2026 (T+90)
64,198 shares@ US$46.730.0043% mcap7.5% of flowCommon StockSEC:0001225208-26-006881:0
2,087 sharesCommon StockSEC:0001225208-26-006362:0
1,010 sharesCommon StockSEC:0001225208-26-006362:1
386,755 shares0Common StockSEC:0001225208-26-005670:0
2,250 shares@ US$55.91950.0002% mcap50.1% of flowCommon StockSEC:0001225208-26-005546:1
Canonical exit: 18 Aug 2026 (T+90)
3,580 shares@ US$56.680.0003% mcap14.1% of flowCommon StockSEC:0001225208-26-005547:0
Canonical exit: 18 Aug 2026 (T+90)
1,770 shares@ US$56.490.0001% mcap100.0% of flowCommon StockSEC:0001225208-26-005548:0
Canonical exit: 18 Aug 2026 (T+90)
2,200 shares@ US$56.94510.0002% mcap49.9% of flowCommon StockSEC:0001225208-26-005546:0
Canonical exit: 17 Aug 2026 (T+90)
24 shares0Common StockSEC:0001225208-26-003179:0
556 shares0Common StockSEC:0001225208-26-003178:0
838 shares0Common StockSEC:0001225208-26-003014:0
6,851 shares@ US$75.768.0% of flowCommon StockSEC:0001225208-26-002794:0
1,413 shares0Common StockSEC:0001225208-26-002139:0
588 shares0Common StockSEC:0001225208-26-002138:0
500 shares0Common StockSEC:0001225208-26-002137:0
1,766 shares0Common StockSEC:0001225208-26-002136:0
25 of 555 declarations
About Boston Scientific CORP
Boston Scientific Corp. is a global medical technology company listed in the United States on the NYSE under the ticker BSX. For French-speaking investors, it is a large-cap healthcare name exposed to structurally attractive end markets driven by aging populations, the rise of chronic disease, and continuous innovation in minimally invasive care. The company was founded in 1979 in Watertown, Massachusetts, and today has its world headquarters in Marlborough, Massachusetts, in the United States. Its corporate identity was built around interventional medicine, with a strategy focused on differentiated technologies and clinical niches where product innovation, physician adoption, and regulatory clearance create meaningful barriers to entry. ([bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2024-annual-report-and-10-K.pdf.coredownload.pdf?utm_source=openai)) Boston Scientific reports through two major segments: MedSurg and Cardiovascular. Its portfolio spans electrophysiology and cardiac rhythm management, left atrial appendage closure, coronary and peripheral interventions, endoscopy, urology, and neuromodulation, along with certain minimally invasive surgical solutions. This diversification gives the company a resilient profile while also supporting above-average growth through a mix of mature franchises and newer platforms. Key product families include WATCHMAN, FARAPULSE, EKOS, EMBLEM MRI S-ICD, and a broad range of endoscopy and urology systems. ([news.bostonscientific.com](https://news.bostonscientific.com/interested-in-our-q4-2024-financial-results?utm_source=openai)) From a competitive standpoint, Boston Scientific ranks among the leading global players in implantable and interventional medical devices, competing with companies such as Medtronic, Abbott, Johnson & Johnson, and Edwards depending on the end market. Its edge comes from portfolio expansion, a strong innovation engine, and disciplined commercial execution across hospitals, electrophysiologists, interventional cardiologists, gastroenterologists, and urologists. The group also has a broad international footprint, with sales across multiple geographies and manufacturing and assembly capacity spread over several sites worldwide. ([bostonscientific.com](https://www.bostonscientific.com/content/dam/bostonscientific/corporate/annual-report/2024-annual-report-and-10-K.pdf.coredownload.pdf?utm_source=openai)) Recent developments reinforce that thesis. Boston Scientific reported first-quarter 2026 net sales of $5.203 billion, up 11.6% year over year, and fourth-quarter 2025 sales of $5.286 billion, with full-year 2025 revenue reaching $20.074 billion. The company also released positive clinical data for FARAPULSE and WATCHMAN, received FDA approvals and clearances for several products, and announced acquisitions including Bolt Medical. For investors, BSX remains a high-quality Healthcare / Pharma stock combining organic growth, innovation, and portfolio leverage on a liquid, closely followed U.S. equity market. ([news.bostonscientific.com](https://news.bostonscientific.com/2026-04-22-Boston-Scientific-announces-results-for-first-quarter-2026?utm_source=openai))
